GSA Capital Partners LLP Takes Position in Kodiak Sciences Inc. $KOD

GSA Capital Partners LLP acquired a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) during the second quarter, Holdings Channel reports. The fund acquired 27,525 shares of the company’s stock, valued at approximately $1,072,000.

Several other large investors also recently made changes to their positions in KOD. Baker BROS. Advisors LP raised its stake in Kodiak Sciences by 15.1% during the 4th quarter. Baker BROS. Advisors LP now owns 19,919,186 shares of the company’s stock worth $556,940,000 after buying an additional 2,608,696 shares during the period. Braidwell LP acquired a new stake in Kodiak Sciences in the fourth quarter valued at approximately $57,955,000. RTW Investments LP acquired a new stake in Kodiak Sciences in the fourth quarter valued at approximately $41,603,000. Janus Henderson Group PLC acquired a new stake in Kodiak Sciences in the fourth quarter valued at approximately $27,950,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Kodiak Sciences by 298.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,303,030 shares of the company’s stock valued at $36,433,000 after acquiring an additional 976,254 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences Stock Performance

NASDAQ KOD opened at $40.98 on Tuesday. Kodiak Sciences Inc. has a 52-week low of $8.29 and a 52-week high of $47.84. The company has a 50-day simple moving average of $39.33 and a 200 day simple moving average of $35.13. The company has a market capitalization of $2.56 billion, a PE ratio of -9.78 and a beta of 2.21.

Kodiak Sciences (NASDAQ:KOD) last released its earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). As a group, analysts forecast that Kodiak Sciences Inc. will post -3.74 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $58.00 target price on shares of Kodiak Sciences in a research report on Monday. Chardan Capital raised shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $14.00 to $61.00 in a research report on Monday, May 11th. JPMorgan Chase & Co. boosted their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. Finally, Wall Street Zen cut shares of Kodiak Sciences from a “hold” rating to a “sell” rating in a report on Saturday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.14.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical?stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.